Retatrutide Dosage Considerations in Special Research Populations The Phase 2 trial enrolled a relatively homogeneous population of adults with obesity or overweight and at least one comorbidity, with a mean baseline BMI of approximately 37 kg/m
(3) While this is a small research sample, another source also confirmed an increase skin thickness, hydration and elasticity
As leaders in healthcare, obesity treatment, or health tech, we can narrow the gap between how these drugs should work and what they do in practice
They are used to treat heart conditions such as High blood pressure (Hypertension), Angina (Chest pain), Heart failure, and Arrhythmias, as well as other conditions like Essential tremor, Migraines, and Glaucoma
Continuous use: ~18% reduction in heart attack, stroke, and death Stop the drug: 6 months +4% risk 1 year +14% 1.5 years benefit erased 2 years +22% risk It takes 3 years to build protection and ~11.5 years to lose it